1. Novel species of myxobacteria will be identified and screened for bioactive compounds.
  2. Innovative biotechnological/ (bio)synthetic approaches will be used to guarantee compound supply as well as create analogs of them.
  3. By combining chemistry with proteomics yet unknown targets of the natural compounds shall be identified.
  4. Finally, with regard to anticancer pharmacology of the myxobacterial compounds the Research Group aims at attractive and promising avenues: We will not only focus on tumor death inducing effects of compounds, but also examine their influence on tumor cell migration, tumor metabolism as well as on cancer immunosurveillance and their underlying signaling pathways.
  5. Besides tumor cells, vascular cells and immune cells known to play a role in cancer survival are in the center of interest for respective pharmacological work.
  6. Complex cellular and in vivo systems as well as pharmacogenomics are employed for first line characterization of promising compounds instead of isolated target screening as usually performed in industrial drug discovery.